Researchers from the Universities of Malaga and Cordoba (Spain) presented data from a study that aimed to identify matrisome regulator miRNAs in obesity and prediabetes that could represent novel noninvasive circulating biomarkers of adipose tissue (AT) fibrosis.
Teva Pharmaceutical Industries Ltd. is partnering with Sanofi SA in a 50-50 collaboration to develop and commercialize its anti-TL1A candidate, TEV ‘574, initially for inflammatory bowel disease (IBD), in a deal that comes with an up-front payment of €469 million (US$500 million) and up to €940 million in development and launch milestones.
Teva Pharmaceutical Industries Ltd. is partnering with Sanofi SA in a 50-50 collaboration to develop and commercialize its anti-TL1A candidate, TEV ‘574, initially for inflammatory bowel disease (IBD), in a deal that comes with an up-front payment of €469 million (US$500 million) and up to €940 million in development and launch milestones.
Researchers have created an artificial intelligence (AI)-enabled implantable bio-sensing device that can change shape and adapt to maintain drug treatment and bypass scar tissue build up. As the foreign body response continues to impact the longevity of implantable medical devices that treat many conditions, the researchers hope that the Fibrosensing Dynamic Soft Reservoir (FSDSR), capable of monitoring fibrotic capsule formation and overcoming its effects via soft robotic actuations, can change the way patients body respond to therapeutic treatments.
Shares in Galecto Inc. (NASDAQ:GLTO) plummeted by 71%, closing Aug. 15 at 67 cents, on news that its lead drug candidate, GB-0139, flamed out in a phase IIb trial in idiopathic pulmonary fibrosis (IPF). The inhaled galectin-3 inhibitor actually performed considerably worse than placebo in the 52-week placebo-controlled study, the endpoint of which was the annual rate of decline from baseline in forced vital capacity (FVC).
Developers of medical technology have many concerns about the U.S. Centers for Medicare & Medicaid Services’ (CMS) handling of coverage and reimbursement, but those controversies have typically revolved around process. A new report sponsored by industry steers a somewhat different tack, however, arguing that while there are issues of process, one key issue is that of funding, a problem that only Congress can remedy.
Histoindex Pte Ltd.'s’s artificial intelligence (AI)-enabled tissue imaging technology more accurately measures the change in fibrosis than current pathology tests, the company said.
Chronic kidney disease (CKD) is the 10th leading cause of death in the United States because of the increased risk for cardiovascular mortality. The major functional cell type of the kidney, tubular epithelial cells (TECs), possess a limited ability to regenerate tissues. Infections can cause proximal G2/M cell cycle arrest, senescence and paracrine secretion of the profibrotic cytokines transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF), which stimulate extracellular matrix production ultimately leading to loss of the epithelial phenotype in TECs. Identification of targets controlling the G2/M cell cycle arrest in TECs may enable the development of therapeutics that can prevent CKD progression.
Vicore Pharma Holding AB grossed about SEK500 million (US$46 million) in a directed share issue that will fund a phase IIb trial of its lead drug candidate, C-21, in idiopathic pulmonary fibrosis (IPF).
